Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock (MINOS)

Mitral regurgitation may be seen in the setting of cardiogenic shock. Transcatheter edge-to-edge repair (TEER) has been shown to improve outcomes in patients with chronic heart failure. Observational studies suggest improvements in clinical outcomes in patients with mitral regurgitation in the setting of cardiogenic shock; however, there remains a lack of randomized clinical data to support the use of TEER in cardiogenic shock.

This study will be a multicenter, open-label, randomized-controlled trial with two study arms: medical therapy and TEER. Patients admitted to the Cardiac Intensive Care Unit (CICU), Cardiac Surgery Intensive Care Unit (CSICU) or Intensive Care Units (ICU) at participating centers will be recruited.

The study aims to answer the question: "Does TEER in patients with SCAI stage C or D cardiogenic with concomitant moderate or greater mitral regurgitation improve outcomes as compared to medical therapy?"

The study hypothesis is that TEER will lead to an overall improvement in the composite outcome as compared to the medical therapy arm.

Study Overview

• Status: Recruiting
• Conditions: Mitral Regurgitation; Cardiogenic Shock
• Intervention / Treatment: Device: Transcatheter edge-to-edge repair; Other: Medical therapy

Detailed Description

Current management strategies for patients with SCAI stage C through E cardiogenic shock include management in a cardiac intensive care unit (CICU) or cardiac surgery intensive care unit (CSICU) with intravenous inotropes (i.e. medications to increase the pumping function of the heart), vasopressors (i.e. medications to increase blood pressure), ventilatory support, and/or mechanical circulatory support. Importantly, with the exception of revascularization, little data exists demonstrating the ability to alter prognosis in patients with cardiogenic shock.

Mitral regurgitation may be seen in the setting of cardiogenic shock. Transcatheter edge-to-edge repair (TEER) has been shown to improve outcomes in patients with chronic heart failure. Observational studies suggest improvements in clinical outcomes in patients with mitral regurgitation in the setting of cardiogenic shock; however, there remains a lack of randomized clinical data to support the use of TEER in cardiogenic shock.

This study will be divided into two phases, as follows:

Phase 1 (Vanguard) - The first phase of this study will be composed of a feasibility stage where a total of 10 participants from centers in Ontario, Canada will be recruited. The primary objective of this phase is to ascertain feasibility of participant recruitment and treatment. Feasibility would be considered met if 10 participants were enrolled 12 months from the date of activation of all four centers.

Phase 2 - The second phase of this study will be a continuation of Phase 1 where the remaining 134 participants, for a total of 144 participants in the overall study. For this second phase of the study, patients will be recruited from high-volume TEER centers in Canada and the United States - with participating centers performing more than 25 TEER procedures per year.

Eligible participants will be randomly assigned in a 1:1 fashion to the medical therapy arm (i.e. control arm) or the TEER arm (i.e. intervention arm) of the trial.

• Study Type: Interventional
• Enrollment (Estimated): 144
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Benjamin Hibbert, MD PhD; Phone Number: 613-696-7115; Email: bhibbert@ottawaheart.ca
• Study Contact Backup: Name: Pietro Di Santo, MD; Phone Number: 15258 613-696-7000; Email: pdisanto@ottawaheart.ca

Study Locations

• Canada
  • Ontario
    • Ottawa, Ontario, Canada, K1Y4W7
      • Recruiting
      • University of Ottawa Heart Institute
      • Contact: Benjamin Hibbert, MD PhD; Phone Number: 613-696-7115; Email: bhibbert@ottawaheart.ca
      • Contact: Baylie Morgan, RN; Phone Number: 19059 613-696-7000; Email: bmorgan@ottawaheart.ca
      • Principal Investigator: Rebecca Mathew, MD
    • Toronto, Ontario, Canada, M4N 3M5
      • Not yet recruiting
      • Sunnybrook Hospital
      • Contact: Andrew Czarnecki, MD; Email: andrew.czarnecki@sunnybrook.ca
    • Toronto, Ontario, Canada, M5B 1T8
      • Not yet recruiting
      • St. Michael's Hospital
      • Contact: Neil Fam, MD; Email: neil.fam@unityhealth.to
• United States
  • Minnesota
    • Rochester, Minnesota, United States, 55905
      • Recruiting
      • Mayo Clinic
      • Contact: Benjamin Hibbert, MD PhD; Email: hibbert.benjamin@mayo.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Participants or substitute decision maker is able and willing to provide written informed consent
2. Age ≥ 18 years
3. SCAI stage C or D cardiogenic shock with persistent inotrope/vasopressor/non-durable mechanical support or unable to wean ventilatory support due to pulmonary edema for 24 hours prior to randomization
4. Greater than or equal to 3+ MR as determined by a study center's transesophageal echocardiogram (TEE)
5. In the opinion of the study center's heart team the participant is anatomically eligible for TMVr with the potential to achieve <3+ MR

Exclusion Criteria:

1. Unwilling or unable to obtain informed consent from the participant or substitute decision maker
2. Revascularization of coronary artery disease performed in the 48 hours prior to randomization
3. If the mechanism of MR is deemed to be degenerative, in the opinion of the heart team the participant is eligible for surgical intervention
4. Prior mitral valve leaflet surgery or implanted mitral valve prosthesis (excluding ring)
5. Echocardiographic evidence of left sided intracardiac mass or thrombus
6. Diagnosis of active infective endocarditis
7. Transesophageal echocardiogram is contraindicated
8. Mitral valve anatomy deemed contraindication to TMVr implantation that cannot be addressed procedurally as determined by the study center's heart team
9. Any aortic valve disease greater than moderate in severity
10. A known hypersensitivity or contraindication to procedure medications which cannot be adequately managed medically
11. Out of hospital cardiac arrest or in-hospital cardiac arrest without documented neurologic recovery
12. Plan for durable mechanical circulatory support implantation prior to TMVr
13. In the opinion of the treating team, there is a significant comorbidity that would limit life expectancy in hospital
14. Pregnant or planning to become pregnant in the next 6 months.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Transcatheter edge-to-edge repair; The experimental arm includes treatment in an intensive care unit with intravenous medications (e.g. vasopressors and inotropes), ventilatory support or mechanical circulatory support plus transcatheter edge-to-edge repair	Device: Transcatheter edge-to-edge repair; Transcatheter edge-to-edge repair; Other Names: MitraClip
Active Comparator: Medical therapy; Medical therapy includes treatment in an intensive care unit with intravenous medications (e.g. vasopressors and inotropes), ventilatory support or mechanical circulatory support.	Other: Medical therapy; Medical treatment in an intensive care unit

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary composite outcome	The primary outcome in this clinical trial will be a composite of in-hospital all-cause mortality, cardiac transplantation, implantation of durable LVAD, or discharge on palliative inotropic therapy.	Through duration of hospitalization, generally up to 12 weeks following admission

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
In hospital all-cause mortality	Death from any cause	Through duration of hospitalization, generally up to 12 weeks following admission
In hospital implantation of durable left-ventricular assist device or cardiac transplantation	Implantation of durable left-ventricular assist device or cardiac transplantation	Through duration of hospitalization, generally up to 12 weeks following admission
Discharge on inotropes	Discharge from index hospitalization on palliative inotropic therapy	Through duration of hospitalization, generally up to 12 weeks following admission
Residual mitral regurgitation	Severity of residual mitral regurgitation as assessed by the core lab on last available in hospital echocardiogram	Through duration of hospitalization, generally up to 12 weeks following admission
Technical success	All of the following must be present: I. Absence of procedural mortality II. Successful access, delivery, and retrieval of the device delivery system III. Successful deployment and correct positioning of the first intended device IV. Freedom from emergency surgery or reintervention related to the device or access procedure.	Measured at exit from procedure room, generally 2 hours after implant
Device success	All of the following must be present: I. Absence of procedural mortality or stroke II. Proper placement and positioning of the device III. Freedom from unplanned surgical or interventional procedures related to the device or access procedure IV. Continued intended safety and performance of the device, including: A. No evidence of structural or functional failure B. No specific device-related technical failure issues and complications C. Reduction of mitral regurgitation to either optimal or acceptable levels without significant mitral stenosis, and with no greater than mild (1+) paravalvular mitral regurgitation (and without associated hemolysis)	At time of discharge from hospitalization, generally up to 12 weeks following admission
Stroke or transient ischemic attack	Acute episode of a focal or global neurological deficit as determined by or in conjunction with the designated neurologist	Through duration of hospitalization, generally up to 12 weeks following admission
Bleeding	Any intracranial bleeding (excluding microhemorrhages <10 mm evident only on gradient-echo MRI); Clinically overt signs of hemorrhage associated with a drop in hemoglobin of ≥5 g/dL or a ≥15% absolute decrease in hematocrit; Fatal bleeding (bleeding that directly results in death within 7 d)	Through duration of hospitalization, generally up to 12 weeks following admission
Vascular access complications	Access site-related arterial or venous injury or injury to surrounding structures	Through duration of hospitalization, generally up to 12 weeks following admission
Cardiac structural complications	Cardiac perforation or pseudoaneurysm	Through duration of hospitalization, generally up to 12 weeks following admission

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
All-cause mortality	Death from any cause	6 months
All-cause hospitalization	Hospitalization is defined as admission to an inpatient unit or ward in the hospital for ≥24 h, including an emergency department stay. Hospitalizations planned for pre-existing conditions are excluded unless there is worsening of the baseline condition.	6 months
Any re-intervention on the mitral valve	Requiring any transcatheter or surgical re-intervention on the mitral valve	6 months

Collaborators and Investigators

• Sponsor: Ottawa Heart Institute Research Corporation

Study record dates

Study Major Dates

• Study Start (Actual): May 26, 2022
• Primary Completion (Estimated): May 1, 2028
• Study Completion (Estimated): May 1, 2028

Study Registration Dates

• First Submitted: February 11, 2022
• First Submitted That Met QC Criteria: March 16, 2022
• First Posted (Actual): March 28, 2022

Study Record Updates

• Last Update Posted (Actual): May 6, 2026
• Last Update Submitted That Met QC Criteria: April 29, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Pathologic Processes; Heart Diseases; Infarction; Necrosis; Heart Valve Diseases; Myocardial Ischemia; Myocardial Infarction; Ischemia; Shock; Pathological Conditions, Signs and Symptoms; Shock, Cardiogenic; Mitral Valve Insufficiency; Therapeutics; Nutrition Therapy
• Other Study ID Numbers: 20210381-01T

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: The IPD sharing plan is to be decided upon at trial completion.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No